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Measuring outcomes in trial-based research is regarded as the ‘gold standard’ methodology to inform policy 
and practice (Rockwood and Gauthier, 2006). While trial methodology and intervention research in the field of 
dementia is not without its critics (Ceci et al, 2020), the full range of trial methods will likely continue to play a 
key role in the development and production of evidence. Dementia care intervention effectiveness trials are 
particularly important. The prevalence of dementia is projected to rise globally, and while pockets of 
innovative policy and practice exist, optimal approaches to facilitate beneficial outcomes for people living with 
dementia are not yet established (McDermott et al, 2019). It is important also not to forget family carers, often 
who are the primary source of support for a person with a diagnosis of dementia. It is critical to understand 
how to support family carers’ strengths and positive psychology (Pione et al, 2020). 
Trials are vitally important but need to be open to critical appraisal. Posing whether it is possible to improve 
the research gold standard is an interesting and very worthy question. Through our recent work on core 
outcomes for people living with dementia we are aware of significant and underlying issues relating to (a lack 
of) stakeholder involvement in the development of measurement instruments and issues on how, why and 
what measurement instruments are chosen.  
 
Stakeholder involvement 
It is pleasing that stakeholder involvement in the development of outcomes and measurement instruments 
has increased in recent years, and there are now many examples of key stakeholders being involved in the 
development of measurement instruments. However, one critique is that often stakeholder involvement is 
limited to providing views on pre-determined outcomes, constructs or domains that researchers and 
professionals have already decided are of interest. Of course, it would be foolish to completely dismiss 
professional expertise which is often accrued over many years of research and or professional practice. Yet 
researchers could and should give greater value to the expertise of lived experience – including in deciding 
what outcomes to measure (Bagley et al, 2016). It is no longer satisfactory to limit stakeholder involvement to 
areas already decided upon by professional groups. The research community is at a relatively early juncture 
when involving stakeholders in the development of outcomes and measurement instruments. In particular it is 
important to facilitate meaningful involvement and avoid tokenistic consultation at all stages of the research 
process (Swarbrick et al, 2016), and this should extend to stakeholder involvement on outcome measurement 
development. It is the only remedy to a rather uncomfortable question; if outcomes and measurement 
instruments are not reflective of what key stakeholders value, can research really claim to create high quality 
or even adequate evidence to inform policies and practices? 
Another pleasing development is the place that stakeholder involvement now has in recent appraisal 
checklists, such as the COSMIN Risk of Bias checklist (Mokkink et al 2018). These are tools with which 
reviewers appraise the quality of outcome measurement instruments. Stakeholder involvement is now part 
and parcel of quality assessments, and this has not always been the case. Progress indeed, but do these 
appraisals capture meaningful stakeholder involvement? Such tools do not really accommodate anything 
beyond reporting that there has been some involvement. Perhaps we should be grateful for this, and it does 
mark progress. But surely we can conceptualise this better. There is an obvious dichotomy in the ontological-
epistemological perspective between rich and deep stakeholder involvement and the philosophy central to 
quantitative measurement. It is worth questioning whether meaningful stakeholder involvement can be 
adequately summarised on the same scale as other quantitative psychometric properties.  
 
What, why and how are outcomes and measures chosen at the macro and micro level 
There is a heterogeneity of outcomes and measurement instruments. There have been a number of attempts 
to attain consensus on outcomes and or measurement instruments that are recommended for use in the 
psychosocial and non-pharmacological fields of dementia research. These consensus exercises are useful, but 
some have not involved people living with dementia (Moniz-Cook et al, 2008), and interestingly the starting 
point tends to be choosing from existing measurement instruments (Webster et al, 2017). Ironically, overall 
there is also inconsistency in the recommendations from these exercises that have sought to provide clarity 
because different measurement instruments are recommended for measuring the same outcome (Harding et 
al, 2020). 
At the micro level of decision-making relating to specific trials, it is the view among some in the research 
community that the inclusion of measurement instruments is often based on that inclusion will be expected, 
as opposed to relating to a theory of change or a sound intervention logic model (Couch et al, 2020). Whether 
this suspicion has merit or not, there is emerging evidence that the use of outcomes and measurement 
instruments may well not be measuring what key stakeholders value (Tochel et al, 2019; Harding et al, 2020). 
For example, cognition and memory performance outcome measures, such as the Mini-Mental State Exam 
(MMSE), dominate dementia trials (Couch et al, 2020). This will not come as a surprise as the MMSE has 
become synonymous with dementia trials, but what is surprising is that the MMSE was not designed as an 
outcome measurement instrument and, as Harrison et al (2016) state in their review of outcome 
measurement instruments, its psychometric properties are poorly or often not described. On the other hand, 
concepts around quality of life and social health are greatly valued by people living with dementia and other 
key stakeholders (Reilly, 2020), and yet these outcomes are used far less frequently (Harrison et al, 2016; 
Couch et al, 2020). For example, quality of life has only been included in 13% of trials (Harrison et al, 2016). 
Social health is still an emerging concept and, while recently developed outcome measurement instruments 
such as the Engagement and Independence in Dementia Questionnaire (EID-Q, see Stoner et al, 2018) we think 
have some overlap, ultimately we are aware of no relevant outcome measurement instrument for social 
health in this field (Harding et al, 2020). In respect of carers, it is the presence of negative aspects such as 
depression and burden that trialists tend to measure (Couch et al, 2020), rather than positive aspects such as 
positive psychology (Pione et al, 2020).  
If outcomes and / or measurement instruments are being included because of a perceived expectation or 
because of out of date assumptions, then there is a danger that trialists are missing things that are important 
to key stakeholders or relate to interventions. Given that many trials often show minimal or no effect (Reilly et 
al; 2015; Woods et al, 2018), are trialists using the ‘right’ measurement instruments that matter to key 
stakeholders, particularly key stakeholders with lived experience? If they are using the ‘right’ measurement 
instruments, and they do in some cases reflect the theoretical focus of interventions, scrutiny should also be 
applied to the focus and characteristics of interventions. Are interventions meaningful and substantial enough 
to affect an outcome? What is clear, at least, is that neither proposition is desirable and both are 
uncomfortable. 
 
The role of core outcome sets and using the best outcome measurement instruments is vital 
If there are questions about the extent of stakeholder involvement in the development of outcomes/measures 
and what, why and how measurement instruments are chosen, perhaps there is a need to sweep aside all 
existing assumptions about outcomes and measurement instruments? At the very least researchers need to 
ascertain which are the best and most robust outcome measurement instruments in a given field, and there 
needs to be some consistency in their application.  
Core outcome set research, if done well, is capable of addressing many of the issues highlighted so far. Core 
outcome set research first asks the question ‘what should be measured as a minimum?’ across all trials to 
increase the ability to compare for effectiveness before asking ‘how to measure?’.  The Core Outcome 
Measures in Effectiveness Trials (COMET) Initiative (http://www.comet-initiative.org/) has spearheaded the 
development of the core outcome set approach (Williamson et al, 2017). The ‘what should be measured?’ 
question tends to be addressed by a multi-phase and mixed methods study design including using literature 
reviews and qualitative research to elicit a ‘long-list’ of existing and new outcomes of interest (Harding et al, 
2019). It is then recommended to use consensus methods such as Delphi surveys and consensus workshops to 
identify the most important – or core - outcomes (Reilly et al, 2020). The involvement of key stakeholders 
throughout is key because then the core outcomes will be aligned to the priorities of key stakeholders, 
including people living with dementia and family carers (; Morbey et al, 2019). To our knowledge there are 
only two published core outcome sets in the field of dementia, concerning people living with dementia in 
relation to physical activity interventions and (Gonclaves et al, 2019) and broader non-pharmacological 
interventions (; 2019, 2020; Morbey et al, 2019; Reilly et al, 2020).  
‘How to measure?’ is best answered using a systematic review of the psychometric properties of outcome 
measurement instruments, including ascertaining face validity assessments of whether measurement 
instruments adequately capture core outcomes (Harding et al, 2020). However, systematic reviews of outcome 
measurement instruments are incredibly important in their own right. This type of research enables the 
selection of the most robust, validated and appropriate outcome measurement instruments. The example by 
Pione et al (2020) in the context of positive psychology measures relating to family carers is a great example of 
how to conduct a review of the psychometric properties of outcome measurement instruments. Researchers 
have a responsibility to adhere to the recommendations made in these type of reviews, and more broadly to 
ensure that the best and most appropriate outcome measurement instruments are used. Arguably, funders 
and journal editors too have a responsibility to encourage researchers to use the best and most appropriate 
outcome measurement instruments. Lest we forget, it is only the application of the ‘best’ outcome 
measurement instruments that can support trialists and intervention research to create the high quality and 
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